Seres Therapeutics
MCRB
133 hedge funds and large institutions have $554M invested in Seres Therapeutics in 2021 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 48 increasing their positions, 33 reducing their positions, and 42 closing their positions.
70% more call options, than puts
Call options by funds: $4.7M | Put options by funds: $2.77M
45% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 33
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.37% less ownership
Funds ownership: 4.71% → 4.34% (-0.37%)
9% less funds holding
Funds holding: 146 → 133 (-13)
31% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 42
71% less capital invested
Capital invested by funds: $1.93B → $554M (-$1.37B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$64M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$47.3M |
| 3 |
Two Sigma Investments
New York
|
+$8.22M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.21M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$7.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$232M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$43.2M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$43.1M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$23.5M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$20.8M |
MCRB Hedge Fund Activity: Q3 2021 in Review
133 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q3 2021, worth a combined $554M — down 71% from $1.93B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of MCRB and 29 opened new positions — a net loss of 13 holders — while 33 trimmed existing stakes and 48 added.
The largest buyer was State Street, adding an estimated $64M. The largest seller was ARK Investment Management, exiting entirely with an estimated $232M sold.
- 133 institutional investors held Seres Therapeutics (MCRB) as of Q3 2021, down from 146 in Q2 2021.
- Funds reported $554M of Seres Therapeutics stock for Q3 2021, down 71% quarter-over-quarter.
- 29 funds opened new Seres Therapeutics positions in Q3 2021 and 42 closed out, a net change of -13 holders.
- The largest Seres Therapeutics buyer in Q3 2021 was State Street, an estimated $64M added.
- The largest Seres Therapeutics seller in Q3 2021 was ARK Investment Management, an estimated $232M sold.
Based on aggregated 13F filings for Q3 2021.